Hong Kong makes belated bid to build biotech business

As Hong Kong belatedly wakes up to the benefits of biotechnology, Singapore streaks ahead.
More than a year after Singapore announced it would invest $1 billion to cultivate start-up biotechnology companies and make life sciences one of the main pillars of its economy, Hong Kong is finally taking action to catch up.

The government's Innovation and Technology Commission has put together a team headed by Sir Colin Dollery, senior consultant to SmithKline Beecham, to study Hong Kong's resources and make recommendations on how it can best take advantage of the genetic revolution.  

It's late to the game. Over the past six years, the government has invested just $100 million in biotechnology-related projects. Those funds have yielded almost nothing in the way of infrastructure or...

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 3 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Share our publication on social media
Share our publication on social media